Improving Fetal Outcomes Through the Use of PGD/PGS

Most of the embryos created during the process of in vitro fertilization (IVF) will not implant. Nearly all of these failures are the result of gen...

Released:

  • Overview

    Most of the embryos created during the process of in vitro fertilization (IVF) will not implant. Nearly all of these failures are the result of genetic defects in the embryos. Thus, the creation of embryos via in vitro fertilization has led to the need to identify possible genetic defects in these embryos before pregnancy occurs. Preimplantation genetic testing is a technique used to identify these embryonic genetic defects. There are currently two pathways for doing so. The first is preimplantation genetic diagnosis (PGD). PGD refers specifically to when one or both genetic parents has a known genetic abnormality and an embryo is tested to determine if it also carries a genetic abnormality. The second pathway is preimplantation genetic screening (PGS). PGS refers to techniques where embryos from presumed chromosomally normal genetic parents are screened for aneuploidy.

    Join us as Drs. Robert Anderson and Brian Kaplan discuss the latest advances in preimplantation genetic screening/diagnosis that will optimize fetal outcomes in ART and the appropriate screening and diagnostic protocols and incorporating the latest technologies into clinical decision-making.

    This program was recorded in advance of the publication of the June 26th ACOG/SMFM Joint Committee Opinion regarding Cell-free DNA Screening for Fetal Aneuploidy. The Opinion can be accessed by clicking here.

    Sponsored by

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Robert E. Anderson, MD
    Medical Director
    Southern California Center for Reproductive Medicine
    Newport Beach, CA

    Disclosure:

    • Robert E. Anderson, MD receives consulting fees from Serono and is a speaker for Illumina Inc.

    Brian Kaplan, MD
    Fertility Center of Illinois
    Chicago, IL

    Disclosure:

    • Brian Kaplan, MD receives consulting fees from Actavis, Ferring, Good Start Genetics, and Serono

    Moderator:
    Michael J. Tucker, PhD, HCLD, FI Biol
    IVF Laboratory Director
    Shady Grove Fertility RSC
    Rockville, MD

    Disclosure:

    • Michael J. Tucker, PhD, HCLD, FI Biol has nothing to disclose.

    The following reviewers/planners/authors have reported real or apparent conflicts of interest that have been resolved:

    • Sean T. Barrett, CHCP has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Robert Schneider has nothing to disclose.
    • Lee Philip Shulman, MD, FACOG, FACMG serves as a consultant for Actavis, Bayer, Merck, Natera, Quest, and Sequenom Inc. and is speaker for Actavis, Bayer, Merck, Pfizer, and Roche.
  • Target Audience

    The target audience for this activity includes Reproductive Endocrinologists, Embryologists, and Certified RE and Embryology Lab Technicians.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the latest advances in preimplantation genetic screening/diagnosis that will optimize fetal outcomes in Assisted Reproductive Technologies (ART)
    • Utilize appropriate preimplantation screening and diagnosis protocols based on the available evidence and guidelines, and incorporate them into clinical decision-making in the IVF laboratory.
  • Provider(s)/Educational Partner(s)

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Illumina Inc.

Facebook Comments

Sign-up for the Global Women's Health Academy newsletters.
Comprehensive Women's Health Education.

Better education for a better you.

* Required
Optional